| Literature DB >> 34113990 |
David C Nguyen1,2, Khalid M Dousa3, Sebastian G Kurz4, Sheldon T Brown5,6, George Drusano7, Steven M Holland8, Barry N Kreiswirth9, W Henry Boom1,10, Charles L Daley11, Robert A Bonomo12,13,14.
Abstract
Mycobacterium abscessus subsp. abscessus is one of the most difficult pathogens to treat and its incidence in disease is increasing. Dual β-lactam combinations act synergistically in vitro but are not widely employed in practice. A recent study shows that a combination of imipenem and ceftaroline significantly lowers the minimum inhibitory concentration of clinical isolates, despite both drugs targeting the same peptidoglycan synthesis enzymes. The underlying mechanism of this effect provides a basis for further investigations of dual β-lactam combinations in the treatment of M. abscessus subsp. abscessus, eventually leading to a clinical trial. Furthermore, dual β-lactam strategies may be explored for other difficult mycobacterial infections.Entities:
Keywords: zzm321990 Mycobacterium abscessuszzm321990 ; L,D-transpeptidase; ceftaroline; dual beta-lactam; imipenem
Mesh:
Substances:
Year: 2021 PMID: 34113990 PMCID: PMC8677594 DOI: 10.1093/cid/ciab535
Source DB: PubMed Journal: Clin Infect Dis ISSN: 1058-4838 Impact factor: 20.999